Key points from article :
Telomir Pharmaceuticals has announced exciting preclinical results showcasing the potential of its compound, Telomir-1, to reverse biological ageing and enhance longevity. Conducted in collaboration with Nagi Biosciences, the study utilized cutting-edge microfluidic technology to examine Telomir-1’s effects on the ageing process in the model organism Caenorhabditis elegans. The results revealed significant benefits, including improved mobility, extended lifespan, and measurable reversal of age-related decline.
The study demonstrated Telomir-1’s ability to enhance healthspan—how long an individual stays healthy during their life—by slowing the ageing process. Improved motility in older organisms and reduced biological age markers were key findings, confirming the compound’s promise in addressing age-related diseases. Telomir Pharmaceuticals is now advancing toward human clinical trials, hoping to translate these findings into therapies that improve quality of life and manage age-associated conditions.
Future research will focus on Telomir-1’s potential to treat progeria, a rare genetic disorder that accelerates ageing in children. Collaborating with the Progeria Foundation, Telomir is testing Telomir-1 on human progeria cell lines and C. elegans models. Additionally, the company is exploring applications for chronic conditions such as diabetes and cancer and plans to investigate the compound’s effects on elderly dogs with osteoarthritis, aiming to improve mobility and joint health.
These results underscore Telomir’s commitment to redefining how we address ageing and related diseases. By combining innovative science with advanced technologies, the company hopes to pave the way for transformative therapies that promote healthier, longer lives.
